FDC Ltd

FDC Ltd, a midcap pharmaceutical company, has faced notable volatility, hitting a 52-week low of Rs. 399.85. The stock has declined 15.44% over the past five days and is underperforming its sector. Additionally, it has dropped 7.73% over the past year, contrasting with the Sensex's gains.

FDC Ltd, a midcap pharmaceutical company, faced significant stock volatility today, with a notable decline. The stock has underperformed its sector and is trading below key moving averages. It is nearing its 52-week low, while the broader market, represented by the Sensex, remains relatively stable.

FDC has announced its financial results for the quarter ending December 2024, revealing a significant shift in performance. The company's evaluation score has been adjusted, indicating challenges in aligning financial metrics. Stakeholders in the pharmaceutical sector will be closely monitoring these developments and their implications.

FDC has recently undergone a revision in its stock evaluation by MarketsMOJO, reflecting concerns over its flat financial performance in the second quarter of FY24-25. Despite a solid annual return, the company's long-term growth metrics and recent declines in profit have prompted a cautious outlook among analysts. FDC has been added to MarketsMOJO's list, highlighting ongoing scrutiny of its financial health.

FDC, a midcap pharmaceutical company, reported flat financial results for the quarter ending September 2024. The company's operating cash flow has been strong in the last three years, but its Profit Before Tax and Profit After Tax have decreased. Non Operating Income accounts for a significant portion of the company's PBT, and its Dividend Payout Ratio is at its lowest in five years. Investors are advised to hold their stock and monitor future financial reports closely.

On November 7th, 2024, FDC, a midcap pharmaceutical company, experienced a -5.01% decline in its stock, in line with the underperformance of the pharmaceutical and drugs industry. Despite this, the stock is still performing well in the long term, with higher moving averages. In comparison to the market, FDC's stock has underperformed but has outperformed in the past month. Investors are advised to hold onto their stocks, according to MarketsMOJO.

On October 31st, 2024, FDC, a midcap pharmaceutical company, saw a 5.85% increase in its stock, outperforming the sector by 3.49%. According to MarketsMOJO, the current call for FDC's stock is 'Hold', based on its recent performance and market conditions. FDC's stock has been on a consecutive gain for 5 days and has outperformed the Sensex by 5.85% in just one day. However, investors should carefully consider their options and seek professional advice before making any investment decisions.

On October 15th, 2024, FDC, a midcap pharmaceutical company, saw a 5.12% increase in its stock, outperforming the sector by 3.74%. This follows two days of decline and is supported by an intraday high of Rs 560.7. According to MarketsMOJO, FDC's stock call is 'Hold' based on current performance and market trends.

FDC, a midcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 615 on September 12, 2024. The stock has outperformed the sector by 5.09% today and is trading higher than its moving averages. FDC's strong presence in the industry and focus on innovation and expansion have contributed to its remarkable growth of 66.65% in the past year.

On September 12, 2024, FDC, a midcap pharmaceutical company, saw a 5.86% increase in its stock price, hitting a new 52-week and all-time high of Rs. 615. The stock has consistently outperformed the sector and market trends, with a current 'Hold' call from MarketsMOJO. Short-term performance also shows strong outperformance compared to the Sensex.

FDC, a midcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on September 12, 2024. The stock is currently trading at Rs 587, 2.86% away from its 52-week high. According to MarketsMOJO, the stock call for FDC is 'Hold', indicating its strong performance but advising caution for investors. FDC has consistently outperformed the sector and is trading higher than its moving averages, showcasing its positive trend. With a remarkable 63.32% increase in stock price in the past year, FDC presents a promising investment opportunity in the pharmaceutical industry.

FDC, a midcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs.600 on September 10th, 2024. The stock has shown a strong performance, outperforming the sector by 3.79% and trading higher than its moving averages. FDC's remarkable performance in the past year can be attributed to its strong presence in the industry and focus on innovation and expansion.

FDC, a midcap pharmaceutical company, experienced a 5.4% rise in its stock price on September 10, 2024, reaching a new 52-week and all-time high of Rs.600. This increase is in line with the company's strong performance in the past month, outperforming the sector by 3.67%. According to MarketsMOJO, FDC's current stock call is 'Hold', based on its consistent upward trend and positive market trends. FDC's success can be attributed to its strong presence in the pharmaceutical industry and promising growth potential as a midcap company.

FDC, a midcap pharmaceutical company, has reached an all-time high in its stock price on September 10th, 2024. The stock is currently trading at Rs 581.75, showing a 2.06% increase from its previous close. FDC's strong performance can be attributed to its consistent growth in the pharmaceutical industry, making it a company to watch out for.

FDC, a midcap pharmaceutical company, has reached a 52-week high with its stock price at Rs. 588.4 on September 9th, 2024. It has been performing well in the market, with consecutive gains in the past two days and trading above its moving averages. FDC's consistent growth of 46.51% in the past year showcases its strength in the competitive pharmaceutical industry.

FDC, a midcap pharmaceutical company, has reached an all-time high stock price of Rs 568.85 on September 9th, 2024. According to MarketsMOJO, the stock is currently rated as 'Hold' based on the company's performance and market trends. FDC has consistently outperformed the Sensex and is currently trading above its moving averages, indicating a positive trend and potential for growth in the pharmaceutical industry.

FDC, a midcap pharmaceutical company, has reached a 52-week high on September 5th, 2024, with its stock currently trading at Rs 577.95. Despite underperforming the sector today, the stock has shown positive performance in the past year and is currently trading higher than its moving averages. According to MarketsMOJO, the stock call for FDC is 'Hold'.

On September 4th, 2024, FDC, a midcap pharmaceutical company, saw a 5.45% increase in its stock price, reaching a new 52-week and all-time high of Rs. 574.9. This positive trend was reflected in the stock call given by MarketsMOJO, rating FDC as a 'Hold'. FDC also outperformed the sector by 4.74% and is currently trading higher than its moving averages, indicating a positive trend. In comparison to the Sensex, FDC's stock showed a 5.45% increase, outperforming the market. With consistent growth and positive performance, FDC is a promising player in the pharmaceutical industry.

FDC, a midcap pharmaceutical company, has reached a 52-week high on September 4th, 2024, with its stock price hitting Rs. 554.55. The company has shown impressive growth in the past year, outperforming the sector and the Sensex. FDC has a strong portfolio and a track record of consistent results, making it a promising player in the pharma industry.